Cialis Indication
Safety Information
Go >View Important Safety Information.
Go >View Full Prescribing Information.
Go >View Full Patient Information.
Register for Updates
Sign up to receive the latest CIALIS treatment information and CialisMD.com updates.
Register >
About ED
CIALIS Clinical Data
Resource Library
To Patient Website
Small Text Regular Text Large Text Adjust Text Size
Fast Fact

Efficacy: For Use as Needed

CIALIS for use as needed can deliver fast onset and efficacy for up 36 hours
  • 16-minute onset in 32% of men taking CIALIS 20 mg (n=75) vs 15% taking placebo (n=74), P<0.05*1,2
  • 30-minute onset in 52% of men taking CIALIS 20 mg vs 35% taking placebo, P<0.05*1,2
  • Efficacy for successful intercourse for up to 36 hours3-5
    • In a separate study designed to assess the efficacy of CIALIS at 36 hours, 62% of intercourse attempts were successful at 36 hours after dosing with CIALIS 20 mg vs 33% with placebo (P<0.001)†4,5
Successful intercourse attempts with CIALIS 20 mg
  • *Onset defined as the earliest time to a successful erection (at least 1 erection in 4 attempts that led to successful intercourse).
  • In 2 studies, men were instructed to attempt intercourse at 24 or 36 hours after taking a single dose of CIALIS. CIALIS was shown to improve, compared to placebo, the ability of men with ED to have a single, successful intercourse attempt at each of these time points. Multiple attempts after a single dose were not evaluated in these studies.
  • †Rates based on mean per-patient intercourse success. Men (n=483) were instructed to attempt intercourse 36 hours after dosing (33 to 39 hours).
  • ‡Results from 5 randomized, 12-week, double-blind, placebo-controlled studies. Data are based on retrospective analysis of intercourse success at selected intervals with CIALIS 20 mg,CIALIS 10 mg, or placebo. Men were instructed to take 1 dose of treatment before sexual activity, with no food restrictions, and were free to choose when to attempt intercourse after dosing.
  • §Rates based on mean per-patient intercourse success. Men (n=483) were instructed to attempt intercourse 36 hours after dosing (33 to 39 hours).

Satisfaction with erection hardness
CIALIS for use as needed delivered high patient satisfaction with erection hardness.¶7

Patient satisfaction with erection hardness
  • Mean per-patient percentage of positive responses to SEP4 among all intercourse attempts was 57% for CIALIS 20 mg (n=1119) vs 19% for placebo (n=625), P<0.0017
  • Successful intercourse (SEP3) rates of 70% and 58% with CIALIS 20 mg (n=253) and CIALIS 10 mg (n=311), respectively, vs placebo 31% (n=300), P<0.001†† ‡‡ 8
  • Retrospective analysis of 11 randomized, 12-week, double-blind, placebo-controlled studies.
  • #Mean per-patient satisfaction calculated across those attempts during treatment for which the patient achieved successful intercourse. All patients with at least one successful intercourse attempt during treatment, as measured by a "yes" response to SEP3, were included in this analysis.
  • ††Results from 5 randomized, 12-week, double-blind, placebo-controlled studies. In the US Academic Centers Study, successful intercourse rates with CIALIS 20 mg (n=146) of 50% vs 25% with placebo (n=49), P<0.001.
  • ‡‡Rates based on mean per-patient intercourse success.

CIALIS gives men with comorbid conditions powerful efficacy

Percent of improved erections in ED patients with comorbidities
  • SEP3 data: Patients with diabetes, hypertension, cardiovascular disease, or benign prostatic hyperplasia had significantly higher successful intercourse rates with CIALIS 20 mg (55%, 63%, 70%, and 65%, respectively) than with placebo (23%, 28%, 34%, and 30%, respectively), P<0.0019
  • The following groups of patients were excluded from clinical trials: those with MI within the last 90 days; unstable angina or angina during sexual intercourse; stroke or heart failure within the last 6 months; uncontrolled arrhythmia; hypotension; uncontrolled hypertension; and hereditary degenerative retinal disorders4
  • §§Retrospective analysis of 11 integrated, 12-week, randomized, double-blind, placebo-controlled trials of 2102 patients with comorbid conditions receiving placebo (n=638), CIALIS 10 mg (n=321), and CIALIS 20 mg (n=1143). Patients with multiple comorbid conditions may have been included in more than one category. Rates based on mean per-patient intercourse success.

For important safety information about CIALIS, click here.

  1. Data on file. Eli Lilly and Company CIA20051130A.
  2. Rosen RC, Padma-Nathan H, Shabsigh R, et al. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med. 2004;1:193-200.
  3. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 pt 1):1332-1336.
  4. Cialis [package insert]. Indianapolis, Ind: Eli Lilly and Company; February 2008.
  5. Young JM, Feldman RA, Auerbach SM, et al. Tadalafil improved erectile dysfunction at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US Trial. J Androl. 2005;26:310-318.
  6. Data on file. Eli Lilly and Company CIA20050729D.
  7. Porst H, Wylie K, Colpi GM, et al. Satisfaction with the hardness of erection and with the overall sexual experience in patients treated with tadalafil. Presented at: 7th Congress of the European Society for Sexual Medicine; December 5-8, 2004. London, England. Poster 164.
  8. Data on file. Eli Lilly and Company CIA20050912D.
  9. Lewis RW, Sadovsky R, Eardley I, et al. The efficacy of tadalafil in clinical populations. J Sex Med. 2005;2:517-531.
  10. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safey of tadalafil: an update. BJU Int. 2004;93:1276-1281.
Important Safety Information | Prescribing Information | Patient Information